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evaluating the structural relevance ofPHAHs
7,8-CDD to the proliferation of endometriosis.
etsofother Therefore, a selection of PHAHs with vary-
Is micewere ing degrees of affinity for the Ah receptor
3, or10 pg were selected. In addition to 2,3,7,8-TCDD,
iCE1s four other PHAHs were administered:
, or10pg 3,3',4,4',5,-pentachlorobiphenyl (PCB 126),
DIkga 10 2,2',4,4',5,5'-hexachlorobiphenyl (PCB
Threeweeks 153), 1,3,6,8-tetrachlorodibenzo-p-dioxin
:bodyliver, (1,3,6,8-TCDD), and 2,3,4,7,8-pen-
sians, tter- tachlorodibenzofuran (4-PeCDF). The
isurement of hypothesis of this study is that induction of
l a 4#-i endometriosis by PHAHs may be Ah recep-
statistically tor-mediated and will be influenced by struc-
either PCB tural differences among these chemicals.
allyobserved 2,3,7,8-TCDD and the two additional diox-
rodue wno in-like compounds (PCB 126 and 4-PeCDF)
1 by 2,3,7,8- (19) should evoke increased proliferation of
ofthis study endometriotic lesions, while the nondioxin-
an-promoted like chemicals (PCB 153 and 1,3,6,8-
*I anamatic TCDD) (19) should not induce increased
Is lx uo-p- endometrioticgrowth.
Materials and Methods
Polyhalogenated aromatic hydrocarbons
(PHAHs) are a group ofenvironmental cont-
aminants that include the polychlorinated
dibenzo-p-dioxins (PCDDs), dibenzofurans
(PCDFs), diphenylethers (PCDEs), biphenyls
(PCBs), and naphthalenes (PCNs) (1,2).
PHAHs evoke a broad range of toxic and
biochemical responses (3,4). One common
adverse effect is reproductive toxicity, includ-
ing reduced fertility, decreased litter size,
diminished uterine weight, and altered ovari-
an functioning in several species (5-7).
Recent studies showed an effect on
endometriosis in several species following
exposure to 2,3,7,8-tetrachlorodibenzo-p-
dioxin (2,3,7,8-TCDD) (8,9). Endometriosis
is the growth of endometrial tissue outside
the uterus, often causing infertility and pain
(10). A major characteristic ofendometriosis
is the presence of lesions and hemorrhagic
cysts in the peritoneum (11). Proliferation of
endometrial lesions is estrogen dependent
(12) and often associated with immune dys-
function (13) and it is possibly caused by
compounds such as the most potent PHAH,
2,3,7,8-TCDD (14). 2,3,7,8-TCDD in-
duced an increase in the prevalence and sever-
ity of endometriosis in rhesus monkeys (8)
and provoked an increase in the growth of
surgically induced endometriotic lesions in
both rats and mice (9) following subchronic
exposure. Because humans are exposed to a
broad range ofPHAHs, identification ofthe
effects ofadditional PHAHs on endometrio-
sis is warranted.
Endometriosis is difficult to diagnosis,
thus estimates of prevalence vary widely.
Many researchers suggest that the preva-
lence of endometriosis is increasing in the
general population (15). While a 10%
prevalence rate in the general population
has often been accepted (10), estimates are
as high as 60-80% among women with
infertility or pain in Belgium (16).
Researchers suggest that the high incidence
rate of endometriosis in Belgian women
coincides with elevated concentrations of
persistent organochlorine environmental
contaminants in this country (17). For
example, elevated blood levels of PCBs
were discovered in Belgian women who
suffer from endometriosis (17). A recent
study in Israel has also demonstrated an
association between endometriosis and ele-
vated 2,3,7,8-TCDD levels (18).
The mechanism of action by which
dioxin induces increased proliferation of
endometriosis in recent animal studies (8,9)
has not yet been determined. Objectives of
this investigation were to determine if
PHAH-promotion ofendometriosis may be
aryl hydrocarbon (Ah) receptor mediated by
Chemicals. Both dioxin-like and nondioxin-
likechemicalswere used inadditionto 2,3,7,8-
TCDD (Radian Corp., Austin, TX) (199.
Dioxin-like chemicals used were PCB 126
(Ultra Scientific Chemical Co., North
Kingstown, RI) and4-PeCDF (Accustandard,
New Haven, CT), and nondioxin-like chemi-
cals used were PCB 153 (Accustandard) and
1,3,6,8-TCDD (Accustandard.) All chemi-
cals had purities greater than 98%. No
2,3,7,8-TCDD-like contaminants were pre-
sent in the other chemicals.
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Animals. Previous studies using rodent
models focused on the effects of 2,3,7,8-
TCDD exposure on the promotion of
endometriosis in rats and mice (9). Because
mice showed agreater degree ofendometriot-
ic severity (9), appeared to lack overt
endocrine disruption at the doses studied (9),
and demonstrated greater immunosensitivity
(20) following exposure to 2,3,7,8-TCDD
than did rats, the mouse model was chosen
for this study. Female B6C3F1 mice were
obtained from Charles River Breeding
Laboratories (Raleigh, NC) at 70 days ofage,
randomly assigned to a treatment group, and
acclimated for 1 week prior to dosing. Mice
were maintained at the National Health and
Environmental Effects Research Laboratory
ofthe U.S. Environmental ProtectionAgency
(EPA). Animal care and treatment were con-
ducted according to established guidelines.
All animals were housed in an environment
with controlled humidity (40-50%), 12:12-
hr light:dark cyde, and constant temperature
(20-24°C). Animals received food (Prolab
rat, mouse, hamster 3000, Agway, Syracuse,
NY) andwater adlibitum
Treatment. Chemical doses were
assigned based on published toxic equiva-
lency factor (TEF) values (3) for all chemi-
cals and solubility considerations for PCB
153 and 1,3,6,8-TCDD. Experiment 1
included doses of 0 (corn oil; Sigma
Chemical Co., St. Louis, MO), 1, 3, and
10 pg 2,3,7,8-TCDD/kg bw with 10 ani-
mals per group. Experiment 2 included
doses of 0, 3, and 30 mg PCB 153/kg bw
and 100, 300, and 1000 pg PCB 126/kg
bw with 10-12 animals per group.
Experiment 3 included doses of 0, 10, 30,
and 100 pg 4-PeCDF/kg bw and 2 and 20
mg 1,3,6,8-TCDD/kg bw with 10-12 ani-
mals per group. Dosing was administered
via oral gavage a total offive times, with 3-
week intervals between each dosing as
described (9). All animals were dosed with
a corn oil dosing vehicle at 10 ml/kg bw.
Surgialtechnique. Because mice have a
closed reproductive tract with a bursa-
enclosed ovary and an estrous cycle instead
of a menstrual cycle, they do not develop
endometriosis naturally (12). Endometriosis
must be induced in these animals through
surgical methods performed during the
week of the second dosing. The two major
steps ofthe surgical process as described by
Vernon and Wilson (21) in a rat model and
extended to mice by Cummings and
Metcalf (12) were 1) ablation of the left
uterine horn with longitudinal bisection to
expose the epithelial cells and 2) suturing of
uterine segments onto alternating mesen-
teric bloodvessels in the peritoneal cavity.
Necropsy. At the conclusion of 16
weeks, the animals were euthanized by
carbon dioxide asphyxiation followed by
exanguination via cardiac puncture.
Necropsies were performed in a random
order to prevent bias during the measuring
of lesion diameters. Lesions, ovaries, uter-
ine horn, liver, and thymus were extracted
and weighed. Lesions, ovaries, and uterine
horns were fixed for histology, while liver
and thymus were frozen on dry ice and
stored at -70°C.
EROD assay. Ethoxyresorufin and
resorufin were purchased from Molecular
Probes (Eugene, OR). Microsomal proteins
were prepared (22) and quantified (23)
using bovine serum albumin (BSA) as a
standard. The reaction buffer contained
0.1 M KPO4, 5 mM Mg2SO4, and 2 mg
BSA/ml at pH 7.5. Liver microsomes were
diluted in 0.1 M KPO4 (100 pl) to provide
reaction linearity, added to 0.1 M KPO4
buffer containing 1.5 nM ethoxyresorufin,
and preincubated for 2 min at 37°C. The
production of resorufin was started by the
addition of 100 pl of ,-NADPH (5
mg/ml) and monitored spectrofluorimetri-
cally as described (22). Alogl0 transforma-
tion was utilized to normalize ethoxyre-
sorufin O-deethylase (EROD) data.
Histopathology. Microscopic examina-
tion of endometriotic lesions and ovaries
was performed to characterize histological
changes associated with exposure to halo-
genated aromatic hydrocarbons (HAHs).
Animals were selected for histopathology
randomly to obtain an unbiased representa-
tive sample for review. Histology was pre-
pared by Experimental Pathology
Laboratories Inc. (Research Triangle Park,
NC) and pathology was performed byJohn
Seely at PATHCO (Research Triangle Park,
NC). Endometriotic lesions were examined
for the presence ofinflammation and lumi-
nal exudate or transudate, while ovaries were
examined for both the presence ofprimary,
growing, and antral follicles and the pres-
ence of corpora lutea (both active and
regressing). Active corpora lutea were
defined as newly formed corpora lutea, as
well as those that became increasingly
eosinophilic and those that appeared foamy.
Regressive corpora lutea were characterized
by degeneration, necrosis, and fibrous tissue
proliferation.
Statistical analysis. Primary statistical
analysis of endometriotic lesion diameters
and secondary analyses of lesion, ovarian,
uterine, and thymus weights from all chem-
ical treatment groups were performed using
the Dunnett's test and a level ofprobability
of statistical significance ofp<0.05. Means
with standard deviations (SD) were deter-
mined for all dose groups for body, liver,
ovarian, uterine, and lesion weights and
lesion diameters. For EROD activity, the
statistical intergroup comparisons were
determined using a one-wayanalysis ofvari-
ance (ANOVA) followed by Fisher's pro-
tected least significant difference (PLSD).
The levels ofprobability ofstatistical signif-
icance for EROD data arep<0.01.
Results
EROD activity is a marker for CYPlAl-
dependent enzyme induction by 2,3,7,8-
TCDD and related compounds (19). In
this study, constitutive EROD activity in
control animals for three separate experi-
ments were similar (Table 1). A statistically
Table 1. Mean parameter values and standard deviations
Dose EROD activity Ovarian
(per kilogram (pmoles/min/ Lesion diameter Lesion weight weight8
Chemical bodyweight) mg protein) (mm) (mg) (mg)
Control 1 0 pg 114 ± 40 5.46 ± 1.27 22.50 ± 13.0 8.51 ± 0.81
2,3,7,8-TCDD 1 pg 201 ± 100 7.27 ± 1.42* 109.20 ± 63.60* 9.11 ± 2.18
3 pg 657 ± 378** 6.96 ± 0.77* 94.50 ± 43.30* 9.30 ± 1.45
10 pg 844± 386** 6.12 ± 0.76 61.70 ± 26.70* 7.03 ± 2.05
Control 2 0 mg 71 ± 27 5.71 ± 1.43 71.30 ± 51.50 8.38 ± 2.98
PCB 153 3mg 116±51 5.74±0.90 59.50±26.20 10.22±1.14
30 mg 91 ± 32 5.84± 0.52 64.10 ± 18.90 13.49 ± 10.57
PCB 126 100 pg 805 ± 408** 6.25 ± 1.03 65.70 ± 28.90 10.68 ± 1.97
300 pg 1576 ± 420** 6.83 ± 1.46 101.00 ± 55.80 9.91 ± 1.56
1000 pg 1827 ± 439** 6.6-1 ± 1.75 91.90± 57.90 9.14± 2.25
Control 3 0 mg 110 ±34 6.05 ± 0.86 71.00 ± 31.70 10.78± 1.81
1,3,6,8-TCDD 2 mg 84 ± 23 5.98 ± 0.91 63.30 ± 27.80 9.17 ± 1.72
20 mg 159 ± 49 5.96 ± 0.82 61.00 ± 29.40 10.38 ± 1.56
4-PeCDF 10 pg 676 ± 293** 6.05 ± 0.54 70.00 ± 22.00 10.42 ± 2.38
30 pg 1303 ± 527** 6.26 ± 1.27 84.20 ± 46.40 9.58 ± 1.72
100 pg 1516 ± 782** 7.32 ± 1.29* 114.30 ± 58.50 9.08± 1.09
Abbreviations: 2,3,7,8-TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; PCB 153, 2,4,5,2',4',5'-hexachloro-
biphenyl; PCB 126, 3,4,5,3',4'-pentachlorobiphenyl; 4-PeCDF, 2,3,4,7,8-pentachlorodibenzofuran, 1,3,6,8-
TCDD, 1,3,6,8-tetrachlorodibenzo-p-dioxin.
aRight ovary of intact uterine horn.
*p<0.05; **p<0.01.
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significant (p<0.01) dose-dependent
increase in EROD activity in mice treated
with increasing doses of 2,3,7,8-TCDD,
PCB 126, or 4-PeCDF was observed; in
contrast, mice treated with 1,3,6,8-TCDD
or PCB 153 had EROD activities similar
to control groups (Table 1).
Previous studies in a rodent model for
2,3,7,8-TCDD-promoted endometriosis
focused on lesion diameter as an indicator
of 2,3,7,8-TCDD-induced responses (9).
Examination of lesion diameter in three
separate control groups in this study indi-
cated similar values with no statistical dif-
ferences (Table 1). Treatment of animals
with 1 or 3 pg 2,3,7,8-TCDD/kg bw
resulted in a statistically significant increase
in lesion diameter (p<0.05). Although the
diameter was increased relative to controls
at 10 pg 2,3,7,8-TCDD/kg bw, it was not
statistically significant (Table 1). An
increase in lesion diameter with dose was
observed in animals treated with 4-PeCDF,
although a statistically significant increase
was only observed in animals treated with
100 pig 4-PeCDF/kg bw (Table 1).
Animals treated with PCB 126 resulted in
an apparent increase in lesion diameter;
however, this increase was not statistically
significant compared to control animals
(Table 1). Analysis of lesion diameter val-
ues for animals treated with PCB 153 or
1,3,6,8-TCDD resulted in lesion diameter
values similar to control animals in all dose
groups (Table 1).
Endometriotic lesion weight was used as
an additional marker to examine HAH-pro-
moted endometriosis. Examination of
lesion weights in three separate control
groups revealed high variability. Lesion
weights for control animals in experiment 1
were significantly different from control
animals in experiments 2 and 3, which may
contribute to the variability in results
among dose and chemical groups (Table 1).
Treatment of animals with 1, 3, or 10 pg
2,3,7,8-TCDD/kg bw resulted in a dose-
dependent decrease in endometriotic lesion
weight. However, endometriotic lesion
weights in all dose groups of 2,3,7,8-
TCDD-treated mice were significantly ele-
vated compared to control animals in
experiment 1 (Table 1). Lesion weights of
animals treated with 1 or 3 pg 2,3,7,8&
TCDD/kg bw also appear elevated when
compared to control animals ofexperiments
2 or 3. Elevated endometriotic lesion
weights were not observed in the lowest
treatment groups for 4-PeCDF or PCB 126
when compared to controls, although an
apparent, but nonsignificant dose-depen-
dent increase in lesion weight was observed
in animals treated with 4-PeCDF/kg bw or
100 or 300 pig PCB 126/kg bw. Lesion
weight values for the highest dose of PCB
126 (1000 pg/kg bw) decreased nonsignifi-
cantly from 300 pg/kg bw. High variability
was present in all treatment groups, espe-
cially in lesion weight data ofanimals treat-
ed with PCB 126 or 4-PeCDF. Analysis of
lesion weights in mice treated with PCB
153 or 1,3,6,8-TCDD resulted in
endometriotic lesion weights similar to con-
trol animals.
Another tissue examined in this study to
assess the effects of HAH exposure on
endometriosis was the ovary. Because body
weight values did notvarysignificantly across
chemical dasses or doses, similar results were
observed between crude ovarian weights
(Table 1) and ovarian weight/bw ratios (data
not shown). Ovarian weights from ablated
uterinehorns appearedslightlylowerthan the
ovarian weights from intact uterine horns.
However, trends in both sets of ovarian
weights are consistent within most dose
groups. Therefore, the crude ovarian weights
from intact uterinehorns (Table 1) were used
as markers to describe the dose-dependent
effects ofadministered compounds on ovari-
an weights. Although no significant differ-
ences in ovarian weight were found in com-
parisons oftreated to control animals, possi-
bly due to high data variability, examination
ofovarian weights from animals treated with
1 or 3 pg 2,3,7,8-TCDD/kg bw revealed a
trend toward an increase in ovarian weights,
which was followed by an apparent decrease
in ovarian weight in animals treated with 10
pg 2,3,7,8-TCDD/kg bw (Table 1). Animals
treated with PCB 153 exhibited an apparent
but nonsignificant increase in ovarian weight
with increasing dose (Table 1). In contrast,
mice treated with PCB 126 or 4-PeCDF
showed an apparent decrease in ovarian
weight with increasing dose (Table 1).
Furthermore, analysis of ovarian weights
from mice treated with 1,3,6,8-TCDD
showed ovarian weights similar to control
animals at all dose levels (Table 1). A micro-
scopic examination ofendometriotic lesions
and ovarian tissue was used to characterize
histological changes associated with exposure.
In all endometrial lesions examined, endome-
trial epithelium, endometrial glands with
stroma, and the myometrium were present,
but these structures varied in thickness and
prominence, without relation to treatment.
The presence ofluminal exudate or transu-
date was more severe in lesions characterized
as nonstandard than in those characterized as
standard, but no significant dose-dependent
distribution ofseverity was noticed because
incidence rates of nonstandard lesions, such
as discolored or hardened lesions, were con-
sistent across dose groups and chemical dass-
es. Inflammation of the endometriotic uter-
ine segments was consistent across all animals
and, in most instances, appeared acute (asso-
ciated with polymorphonuclear cells.)
Examination of ovarian tissue revealed the
absence of active corpora lutea in animals
only from the 10 pg 2,3,7,8-TCDD (in two
ofthree animals examined), 100 pg PCB 126
(one of three animals), and 1000 pig PCB
126/kg bw (two ofthree animals) treatment
groups. In addition, animals with the highest
number ofregressive corpora lutea compared
to total corpora lutea (both active and regres-
sive) were animals treatedwith 10 pg2,3,7,8-
TCDD (53.3%), 100 pg PCB 126 (60%), or
1000 pig PCB 126/kg bw (75%). In contrast,
only 26.7% ofthe total corpora lutea in con-
trol animals, was characterized as regressive.
Table 2. Mean parameter values and standard deviations
Dose Uterine
(per kilogram horn weighta Thymusweight Liverweight
Chemical bodyweight) (g) (g) (g)
Control 1 0 pg 0.069 ± 0.016 0.031 ± 0.012 1.247 ± 0.107
2,3,7,8-TCDD 1 pg 0.060 ± 0.020 0.035 ± 0.014 1.359 ± 0.148
3 pg 0.074 ± 0.029 0.048 ± 0.022 1.323 ± 0.115
10 pg 0.058 ± 0.020 0.031 ± 0.013 1.581 ± 0.159
Control 2 0 mg 0.050 ± 0.023 0.033 ± 0.004 1.238 ± 0.140
PCB 153 3 mg 0.057 ± 0.019 0.035± 0.010 1.291 ± 0.166
30 mg 0.058 ± 0.020 0.042 ± 0.011 1.306 ± 0.146
PCB 126 100 pg 0.049 ± 0.008 0.043 ± 0.012 1.410 ± 0.160
300 pg 0.058 ± 0.015 0.031 ± 0.012 1.367 ± 0.151
1000 pg 0.053 ± 0.011 0.028 ± 0.008 1.521 ± 0.128
Control 3 0 mg 0.061 ± 0.017 0.036 ± 0.005 1.329 ± 0.081
1,3,6,8-TCDD 2 mg 0.053 ± 0.014 0.039 ± 0.009 1.197 ± 0.087
20 mg 0.061 ± 0.016 0.041 ± 0.007 1.300 ± 0.182
4-PeCDF 10 pg 0.063 ± 0.015 0.036 ± 0.007 1.359 ± 0.131
30 pg 0.060 ± 0.029 0.027 ± 0.008* 1.440 ± 0.310*
100 pg 0.052 ± 0.023 0.026 ± 0.006* 1.467 ± 0.211*
Abbreviations: 2,3,7,8-TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; PCB 153, 2,4,5,2',4',5'-hexachloro-
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The absence ofactive corpora lutea and the
high percentages ofregressive corpora lutea in
these dose groups indicate either a direct or
indirectchemically induced atrophic effect on
the ovaries in these animals.
The final parameters measured in the
study were uterine, thymus, and liver
weights. Uterine weights of all treated ani-
mals were not statistically different from val-
ues ofcontrol animals, and analysis ofuter-
ine weights for three separate control experi-
ments revealed no statistical differences
(Table 2). There was an apparent nonsignif-
icant increase in uterine weights of mice
treated with 3 pg 2,3,7,8-TCDD/kg bw,
which was followed by an apparent decrease
in uterine weights in the highest dose group,
10 pg 2,3,7,8-TCDD/kg bw. These effects
on uterine weights were similar to those
observed in animals treated with PCB 126.
A trend toward a slight decrease in uterine
weights with increasing dose of 4-PeCDF
was observed. Treatment ofanimals with all
doses ofPCB 153 resulted in a slight, non-
significant dose-dependent increase in uter-
ine weights as compared to controls.
However, all animals treated with 1,3,6,8-
TCDD had uterine weights similar to con-
trol animals. In contrast, a dose-dependent
decrease in thymus weights with increasing
dose of4-PeCDF or PCB 126 was observed
(Table 2). Thymus weights ofanimals treat-
ed with 30 or 100 pg 4-PeCDF/kg bw were
significantly less than control thymus
weights (p<0.05), while the suggested
decrease in thymus weights in animals treat-
ed with PCB 126 was nonsignificant.
Finally, treatment of animals with 2,3,7,8-
TCDD, PCB 126, or 4-PeCDF resulted in
an apparent increase in liver weight with
increasing dose, although this was only sig-
nificant in animals treated with the middle
and high doses of 4-PeCDF (Table 2). In
contrast, exposure ofanimals to PCB 153 or
1,3,6,8-TCDD resulted in liver weights in
all dose groups similar to controls.
Discussion
The promotion of endometriosis only by
PHAHs with high binding affinity to the
Ah receptor is consistent with the hypothe-
sis that PHAH promotion ofendometriosis
is Ah receptor mediated. Due to variability
in these results from study limitations such
as individual animal variability, bioassay
insensitivity, and gross invasiveness of the
surgical procedures, conclusions about the
mechanism ofaction by which HAHs pro-
mote endometriosis are only preliminary.
Follow-up studies should attempt to refine
the surgical model to more accurately assess
the effects ofHAHs on endometriosis.
As in previous studies that focused on
lesion diameter as the primary endpoint to
assess the influence of 2,3,7,8-TCDD on
the promotion of surgically induced
endometriosis (9), this study evaluated the
effects of 2,3,7,8-TCDD, PCB 126, PCB
153, 1,3,6,8-TCDD, and 4-PeCDF on
endometriotic lesion diameter (Table 1).
The mechanism by which PHAHs such as
2,3,7,8-TCDD, PCB 126, or 4-PeCDF
increase lesion diameter is unknown, but it
appears to be Ah receptor mediated, as is
true for all other well-characterized 2,3,7,8-
TCDD-induced responses (24).
Structure binding relationships (SBRs),
based on affinity of ligand binding for the
Ah receptor, are often indirectly assessed by
induction of arylhydrocarbon hydroxylase
(AHH), EROD, and other enzyme activities,
and are described by structure-activity rela-
tionships (SARs). Previous studies showed a
correlation between endpoints, such as
CYPlAl induction, and affinity for the Ah
receptor expressed through SARs (25). For
example, in this study 2,3,7,8-TCDD, PCB
126, and 4-PeCDF, the congeners that
increased endometriotic lesion diameters
(statistically significant only in animals treat-
ed with 2,3,7,8-TCDD or 4-PeCDF), have
the strongest binding affinities for the Ah
receptor (1,26,27). In contrast, compounds
such as 1,3,6,8-TCDD and PCB 153, which
did not induce any increases in endometriot-
ic lesion diameter, have weak affinities
towards theAh receptor (27,28).
Endometriotic lesion weights were also
measured for secondary analysis ofchanges
in endometriotic lesion sizes due to HAH
exposure (Table 1). Increases in lesion
weight, like increases in lesion diameter,
occured in animals exposed to chemicals
with the highest affinities for the Ah recep-
tor (statistically significant increases
induced by 2,3,7,8-TCDD and nonsignifi-
cant increases induced by PCB 126 and 4-
PeCDF) and not in animals exposed to
chemicals with significantly lower binding
affinities (PCB 153 and 1,3,6,8-TCDD).
This supports the hypothesis that promo-
tion ofendometriosis by HAHs may be Ah
receptor mediated.
This study also revealed changes in
ovarian weight and differences in ovarian
histopathological evaluation based on
chemical and dose (Table 1). As with other
endpoints, chemicals with greater binding
affinities for the Ah receptor evoked greater
toxic responses such as decreases in ovarian
weights. Ovarian histological examination
of animals treated with 1 or 3 pg 2,3,7,8-
TCDD/kg bw, PCB 153, 1,3,6,8-TCDD,
or 4-PeCDF was consistent with ovarian
weights for these animals and indicated no
presence ofovarian atrophy. The absence of
corpora lutea and the high percentages of
regressive corpora lutea in animals treated
with 10 pg 2,3,7,8-TCDD, or 100 or 1000
pg PCB 126/kg bw supports the hypothesis
that ovarian atrophy may have occurred in
animals treated with high doses of chemi-
cals with strong binding affinities for theAh
receptor. The lack of ovarian atrophy
observed in the 4-PeCDF-treated animals
may be due to the low concentration of4-
PeCDF available to extrahepatic tissues due
to its sequestration in the liver (29). Still,
the results ofthe histological evaluations are
preliminary because only a small, randomly
selected representative sample from each
dose group was examined.
Ovarian atrophy at high doses of
2,3,7,8-TCDD and PCB 126 is consistent
with the results of decreased lesion diame-
ters and weights observed in animals
administered high doses of these com-
pounds compared to the resulting lesion
diameters and weights in animals adminis-
tered lower doses. High doses of PHAHs
may cause antiestrogenic effects, leading to
either indirect or direct ovarian toxicity or
atrophy (30). The resulting decrease in the
promotion of endometriosis (observable in
the variability in lesion diameter and lesion
weight values at the high dose levels of
2,3,7,8-TCDD and PCB 126) is consistent
with the requirement for estrogen to pro-
mote lesion growth (31). Thus, Ah recep-
tor binding may correlate with ovarian
atrophy, as well as lesion diameter and
lesion weight. Future studies examining
endometrial promotion should use lower
dose levels of2,3,7,8-TCDD and PCB 126
to avoid adverse effects on the ovary.
Several additional endpoints were mea-
sured in this study to assess the adverse
effects of PEHIAH exposure. Resulting antie-
strogenic effects from HAH exposure could
also be mediated by an indirect route via a
decrease in the concentration of circulating
estrogens (32). This can also lead to a
decrease in uterine weights (33). Analysis of
uterineweights in this studyrevealed a corre-
lation between changes in uterine weights
and binding affinities for the Ah receptor.
Chemicals that bind strongly to the Ah
receptor (2,3,7,8-TCDD, PCB 126, and 4-
PeCDF) caused decreases in uterine weights
at high doses, while chemicals that bind
weakly to the Ah receptor (PCB 153 and
1,3,6,8-TCDD) evoked no apparent
decreases in uterine weights when compared
to controls. Also, even though changes in
uterine weights were not statistically signifi-
cant, they appeared to correlate with changes
in ovarian weights and ovarian histopatho-
logical evaluations, supporting the theory of
ovarian atrophy in animals treated with the
highest doses of 2,3,7,8-TCDD or PCB
126. Therefore, a relationship appears to
exist between structure-activity and binding
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relationships and antiestrogenic effects, such
as decreases in uterine weights.
Another significant effect often associat-
ed with 2,3,7,8-TCDD exposure is thymic
atrophy, shown by previous studies to be
Ah receptor mediated (25). Originally, this
study design was for levels of chemical
exposure to produce no overt toxicity.
However, analysis ofthymic atrophy in this
study revealed decreases in thymus weights
only at high doses of chemicals with high
binding affinities for the Ah receptor
(2,3,7,8-TCDD, PCB 126, and 4-PeCDF);
this was only statistically significant in ani-
mals treated with either of the two highest
doses of 4-PeCDF. Therefore, the mecha-
nism ofthymic atrophy correlates with the
structural relationships ofPHAHs observed
in mice with endometriosis.
Hepatotoxicity is a common response
in mice following exposure to PHAHs (32)
and often results in increased liver weights
(34). In this study, nonsignificant increased
liver weights with increasing dose were
apparent only in animals treated with
2,3,7,8-TCDD or PCB 126, while statisti-
cally significant increases were apparent in
animals treated with 4-PeCDF. A greater
hepatotoxic response may have been
observed in animals treated with 4-PeCDF
than in animals treated with 2,3,7,8-
TCDD or PCB 126 because 4-PeCDF is
sequestered in the liver (29). Because these
chemicals bind with great affinity to theAh
receptor, increases in liver weight and
hepatotoxicity appear to correlate with
binding affinities for theAh receptor.
In addition to induction of toxic
responses such as thymic atrophy and hepa-
totoxicity, PHAHs have been identified as
microsomal monooxygenase inducers (35),
frequently inducing cytochrome P450
isozymes (36). CYP4501A1 enzyme induc-
tion is often measured by AHH or EROD
activity. Increased enzyme activity coincides
with increased gene expression and PHAH
exposure (37). Therefore, EROD activity
was measured in this study as an indicator of
PHAH-induced effects and to interpret
information about endometrial growth.
Based solely on analysis of EROD activities
(Table 1) for animals treated with PCB 126
versus animals treated with 2,3,7,8-TCDD,
lesion size of animals treated with the 100
pg PCB 126/kg bwshould be comparable to
lesions in animals treated with 10 pg
2,3,7,8-TCDD/kg bw. Thus, lesion diame-
ters ofanimals treatedwith PCB 126 should
have decreased with increasing dose as did
lesion diameters in animals treated with the
highest dose of 2,3,7,8-TCDD when com-
pared to lower doses. This effect is most
probably the result of ovarian atrophy as
seen histologically. Even though the EROD
values of animals treated with the highest
dose of 4-PeCDF were comparable to
EROD values in animals treated with 300
pg PCB 126/kg bw, no ovarian atrophy was
observed in these animals, possibly because
ofthe lack ofavailability ofthis chemical to
extrahepatic tissue due to its extensive
sequestration in the liver (29). Thus, lesion
diameters continued to increase because no
ovarian atrophy occurred and circulating
estrogen levelswere probably normal.
In conclusion, this studywas an analysis
of the influence of the structural relevance
ofPHAHs on the proliferation ofsurgically
induced endometriotic lesions in B6C3F1
female mice. Analysis of all the parameters
measured, especially lesion diameter, sug-
gests that the mechanism of PHAH-pro-
moted endometriosis may be Ah receptor
mediated, with structure-activity and bind-
ing relationships influencing the degree of
endometriotic proliferation.
Some endpoints in this study, such as
endometriotic lesion diameter, did not corre-
late directly with dose level or hepatic
EROD induction because of influences of
additional responses such as hormonal inter-
actions and possible antiestrogenic effects.
Chemicals exerting antiestrogenic effects at
high doses can induce ovarian atrophy,
which in turn maydecrease circulating estro-
gen levels and proliferation ofendometriosis.
In general, the responses in lesion diameter,
lesion weight, ovarian weight, uterine
weight, and thymus weight correlate with
structure binding relationships ofthe admin-
istered PHAHs. Specifically, analysis of the
primary endpoint measured, endometriotic
lesion diameter, demonstrates a dose-depen-
dent increase in size following administration
of chemicals with strong binding affinities
for theAh receptor, when the effects ofovar-
ian atrophy on lesion diameter are con-
trolled. Therefore, the results of this study
provide preliminary support for thehypothe-
sis that PHAH promotion ofendometriosis
maybeAh receptor mediated.
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The conference Risk 97will be held October 21-24, 1997, in Amsterdam and is organized by RIVM, in
cooperation with various international organizations. The central theme ofthe conferencewill be the relevance
ofgeographical maps forthe discussion on and the managementof risks. Risk conceptsweredeveloped in
various, widelydiffering fields ofscience and policy. Within theenvironmental sciences, differences in
approach can also be distinguished, e.g., between radiological risks, risks ofcarcinogenic compounds, and
ecotoxicological risks. Whereas the assessmentof radiological risks for humans is largely regulated, the
methods forassessing risks oftoxic compounds for humans and the ecosystem are still developing. However,
in all these disciplines the application ofgeographical information and transferring estimated riskvalues into
maps are emerging. Although theaims of riskassessments in each ofthese fields are similar, the terminology
and the methods differwidely, which creates profound difficulties in policy making and negotiations with the
parties involved, such as industries and the public. The conference aims to bring these subjects togetherto
advance mutual understanding and thetechnologyof risk mapping.
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